# NBMI Treatment in Patients With Mercury Toxicity

> **NCT04183595** · PHASE2,PHASE3 · UNKNOWN · sponsor: **EmeraMed** · enrollment: 116 (estimated)

## Conditions studied

- Mercury Poisoning

## Interventions

- **DRUG:** (N1, N3-bis(2- mercaptoethyl)isophthalamide)
- **OTHER:** Excipients microcrystalline cellulose, silica and magnesium stearate

## Key facts

- **NCT ID:** NCT04183595
- **Lead sponsor:** EmeraMed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-22
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-11-22
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183595, "NBMI Treatment in Patients With Mercury Toxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04183595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*